Company Overview and News

 
Trading ideas: Crest Builder, Pasukhas, Tien Wah, PUC, Comintel

2018-03-21 thestar.com.my
KUALA LUMPUR: JF Apex Research expects Crest Builder Holdings Bhd , Pasukhas Group Bhd , Tien Wah Press Holdings Bhd , PUC Bhd and Comintel Corp Bhd to be among the stocks to watch today.

 
Crest Builder shares rise 2% on RM328m contract win

2018-01-24 thestar.com.my
KUALA LUMPUR: Crest Builder Holdings Bhd ’s share price rose 2% this morning on news of it securing a RM328million construction contract.

 
Trading ideas: KPJ Healthcare, IGB Reit, Caring Pharmacy, Crest Builder

2018-01-24 thestar.com.my
KUALA LUMPUR: KPJ Healthcare , IGB Real Estate Investment Trust (IGB Reit), Caring Pharmacy Group Bhd, Crest Builder Holdings Bhd , Samchem Holdings Bhd and Green Packet Bhd are among the stocks to watch on Wednesday, according to JF Apex Research.

 
Trading ideas: Crest Builder, CIMB, CCM

2018-01-19 thestar.com.my
KUALA LUMPUR: Crest Builder Holdings Bhd , CIMB Group and Chemical Company of Malaysia Bhd (CCM) are among the stocks to watch on Friday, according to JF Apex Research.

 
Malaysia's construction sector to normalise to RM25 bil this year, says HLIB Research

2017-01-04 theedgemarkets
KUALA LUMPUR (Jan 4): The Malaysian construction sector is expected to see downward normalisation this year, in which the domestic contract is projected to come in at RM25 billion, after achieving a record higher base in 2016, according to Hong Leong IB Research (HLIB).

 
Breakfast briefing: Thursday, October 13

2016-10-13 thestar.com.my
MarketWrap: The S&P 500 and the Dow Jones industrial average indexes ended Wednesday's session with small gains as expectations for timing on a rate hike were largely unchanged after US Federal Reserve minutes and investors waited on earnings reports. - Reuters The DJIA rose 15.54 points, or 0.09%, to 18,144.2, the S&P 500 gained 2.45 points, or 0.11%, to 2,139.18 and the Nasdaq dipped 7.77 points, or 0.

 
KLCI to trade range bound, hover at 1,670 level

2016-10-12 theedgemarkets
KUALA LUMPUR (Oct 13): The FBM KLCI  is expected to trade range bound today and hover around the 1,670 points level, following the dour overnight close at most global markets.

 
MTD ACPI, Perisai, N2N Connect, Hibiscus, Crest Builder, Zhulian, Scicom and Top Glove

2016-10-12 theedgemarkets
KUALA LUMPUR (Oct 12): Based on corporate announcements and news flow today, companies that may be in focus tomorrow (Thursday, Oct 13) could include: MTD ACPI Engineering Bhd, Perisai Petroleum Teknology Bhd, N2N Connect Bhd, Hibiscus Petroleum Bhd, Crest Builder Holdings Bhd, Zhulian Corp Bhd, Scicom (MSC) Bhd and Top Glove Corp Bhd.   MTD ACPI Engineering Bhd, responding to a media report that it may become a reverse takeover vehicle for a construction outfit, confirmed today that it has received several corporate proposals from various parties.

 
Hwa Tai, Solution Engineering, SLP, Crest Builder, Astral Supreme

2016-06-14 www2.theedgemarkets
KUALA LUMPUR (June 14): theedgemarkets.com highlighted five stocks with momentum at Bursa Malaysia's afternoon market close today. Three stocks showed positive momentum while two had negative momentum.   Stocks that showed positive momentum were :

 
Breakfast briefing: Tuesday, June 14

2016-06-14 thestar.com.my
MarketWrap: Wall Street stumbled for a third straight session on Monday as tech stalwarts Microsoft and Apple dragged on indexes and investors braced for major economic and political events in the United States and Europe. - Reuters The DJIA closed down 132.86 points, or 0.74%, to 17,732.48, the S&P 500 lost 17.01 points, or 0.81%, to 2,079.06 and the Nasdaq dropped 46.11 points, or 0.94%, to 4,848.

 
Crest Builder clinches RM438mil contract

2016-06-13 thestar.com.my
PETALING JAYA: Crest Builder Holdings Bhd has clinched a RM438.3mil contract to build residential and commercial buildings at Sime Darby Property’s KL East development in Setapak.

 
Crest Builder unit gets RM438m construction job from Sime Darby

2016-06-13 www2.theedgemarkets
KUALA LUMPUR (June 13): Crest Builder Holdings Bhd's unit Crest Builder Sdn Bhd has clinched a construction contract from Sime Darby Bhd's unit Sime Darby Melawati Development Sdn Bhd worth RM438.29 million.

 
Eye on stock

2016-06-04 thestar.com.my
CREST Builder Holdings Bhd (Cresbld, Code 8591) shares dropped to a three-year low of 84 sen on April 8 amid extended correction process.

 
Breakfast briefing: Thursday, April 21

2016-04-21 thestar.com.my
MarketWrap: Wall Street ended less than 2% short of a record-high close on Wednesday as a rebound in oil prices added to optimism sparked by a raft of earnings reports. Driven 15% higher since mid-February by a recovery in weak oil prices and helped by a softer dollar, the S&P 500 stood less than 30 points below last May's all-time peak. - Reuters DJIA rose 0.24% to end at 18,096.27 points, the S&P 500 gained 0.

 
Breakfast briefing: Wednesday, April 20

2016-04-20 thestar.com.my
MarketWrap: The S&P 500 climbed closer to a record high on Tuesday, lifted by energy stocks and a solid quarterly report from Johnson & Johnson. After dipping into negative territory and then recovering, the S&P 500 ended less than 2% short of last May's record high close, with investors laser-focused on a growing flow of first-quarter earnings scorecards. - Reuters DJIA rose 0.27% to 18,053.6 points, the S&P 500 gained 0.

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

13h - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

13h - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...